Core Viewpoint - Artelo Biosciences, Inc. has been upgraded from Hold to Buy by D. Boral Capital, with a price target of $20, highlighting its focus on Cachexia and chemotherapy-induced peripheral neuropathy (CIN) [1] Group 1: Drug Development and Pipeline - ART27.13, a Phase 2 asset, is a selective benzimadazole agonist acquired from AstraZeneca, showing potential to stimulate appetite and promote weight gain, which could improve the quality of life for cancer patients [1][2] - ART26.12, another asset licensed from the University of Stonybrook, appears to protect nerves from damage without compromising chemotherapy efficacy, with favorable results from its first-in-human study affirming its safety and pharmacokinetic profile [3] - New preclinical data on ART12.11, a Cannabidiol and Tetramethylpyrazine cocrystal drug candidate, was presented, indicating its potential for treating depression and anxiety, particularly in patients with cognitive dysfunction [4][6] Group 2: Efficacy and Market Position - ART12.11 demonstrated significant behavioral improvements in male rats under chronic stress, showing efficacy comparable to sertraline (Zoloft), a leading SSRI, while also reversing stress-induced memory deficits [6][7] - Artelo Biosciences stock increased by 14.66% to $16.42 following these developments, reflecting positive market sentiment [6]

Core Insights - ZyVersa Therapeutics is advancing its Cholesterol Efflux Mediator VAR 200, which has received FDA authorization for Emergency Compassionate Use in a patient with ApoCII amyloidosis [2][3] - The company is conducting a Phase 2a clinical trial for diabetic kidney disease (DKD) to gather data that will support the ongoing development of VAR 200 [3][4] - ZyVersa has entered into a warrant inducement agreement with an institutional investor, raising $2 million through the exercise of Series A-2 and A-3 warrants at a reduced price [7] Company Developments - VAR 200 is an injectable drug in Phase 2 development aimed at reducing renal lipid accumulation, which is critical for kidney health [4][5] - Preclinical studies have shown that VAR 200 can lower cholesterol and lipid levels, protect against renal injury, and improve proteinuria in animal models [5][6] - The company is exploring additional indications for VAR 200, including Alport Syndrome and diabetic kidney disease, as part of its indication expansion strategy [6] Market Performance - ZyVersa's stock (ZVSA) experienced a significant increase of 56%, reaching $1.03, with a trading volume of 160.9 million shares compared to the average of 4.03 million [1][7]

Core Viewpoint - Shares in Recursion Pharmaceuticals surged over 12% due to a de-risking event in its drug discovery pipeline related to the acquisition of a 50% interest in the ENPP1 inhibitor program REV102 from Rallybio [1][2] Group 1: Acquisition Details - Recursion acquired the remaining 50% interest in the ENPP1 inhibitor program REV102, which is being developed to treat hypophosphatasia (HPP), a rare genetic disorder affecting bone development [2][3] - The joint venture with Rallybio has resulted in the development of REV102, which is currently in the preclinical stage [3] Group 2: Financial Terms of the Deal - The deal includes an upfront equity payment of $7.5 million, an additional equity payment of $12.5 million if REV102 undergoes further preclinical trials, and a $5 million milestone payment upon initiation of dosing in a phase 1 study [6] - Recursion will also receive low-single-digit royalties on future sales of REV102 [6] Group 3: Implications for Development - The agreement reduces the risk associated with the development of REV102 and alleviates uncertainties related to Rallybio's financial condition, thereby adding value to Recursion's pipeline [7]

Market Overview - U.S. stocks showed mixed performance with the Dow Jones index declining by 0.35% to 44,249.09, while the NASDAQ increased by 0.07% to 20,427.63 and the S&P 500 fell by 0.03% to 6,228.39 [1] - Energy shares experienced a notable increase of 2.1%, while utilities stocks decreased by 1.9% [1] Used Vehicle Market - The US Manheim Used Vehicle Value Index rose by 1.6% month-over-month for June, following a 1.4% decline in May [2][11] Commodity Market - Oil prices increased by 0.3% to $68.14, while gold prices decreased by 1.1% to $3,306.90. Silver fell by 0.8% to $36.625, and copper dropped by 0.5% to $5.0000 [5] European Market - European shares showed positive movement with the eurozone's STOXX 600 rising by 0.40%, Spain's IBEX 35 Index up by 0.10%, London's FTSE 100 gaining 0.46%, Germany's DAX 40 increasing by 0.68%, and France's CAC 40 rising by 0.46% [6] Asian Market - Asian markets closed higher, with Japan's Nikkei gaining 0.26%, Hong Kong's Hang Seng climbing 1.09%, China's Shanghai Composite increasing by 0.70%, and India's BSE Sensex rising by 0.32% [7] Company News - ENDRA Life Sciences Inc. saw its shares surge by 134% to $8.10 after announcing a US patent for a "Radio Frequency Applicator" [9] - ProKidney Corp. shares surged by 218% to $1.95 following positive topline results from its Phase 2 REGEN-007 trial for chronic kidney disease and diabetes [9] - Humacyte, Inc. shares increased by 20% to $2.5750 after receiving Electronic Catalog Listing approval from the US Defense Logistics Agency [9] - Blue Gold Limited shares dropped by 21% to $58.75 after announcing the formation of its inaugural Advisory Board for Blockchain Evolution [9] - Sunrun Inc. shares fell by 11% to $9.84 after President Trump signed an executive order to end clean-energy tax credits [9] - Apogee Therapeutics, Inc. shares decreased by 8% to $36.24 following the release of data from its Phase 2 APEX clinical trial for atopic dermatitis [9]

Maintain BUY. We are positive on the global potential of Innovent's rich innovative pipelines. Innovent is on track to achieve EBITDA breakeven this year. Backed by smooth development of IBI363, we improved our possibility of success for the asset and raised our DCF-based TP to HK$102.95 from HK$94.74. 机构：招银国际 研究员：Jill WU/Andy WANG IBI363 positioned as a promising next-generation IO therapy with Ph3 trials underway. Strong survival benefits and broad potential position IBI363 (PD-1/IL-2) as a potential bloc ...

Company Overview - CARBIOS is a biotech company focused on developing and industrializing biological solutions to reinvent the life cycle of plastics and textiles, aiming to reduce pollution and promote a circular economy [4]. - The company has two main technologies: biorecycling of PET and biodegradation of PLA, both of which are reaching industrial and commercial scales [4]. - CARBIOS has been recognized scientifically, including features in prestigious publications like Nature, and collaborates with major brands in various industries to enhance product recyclability [4]. Liquidity Contract and Financial Performance - As of June 30, 2025, CARBIOS reported assets on its liquidity account as part of a contract with Natixis ODDO BHF [2][3]. - The liquidity contract is in accordance with the French Financial Market Authority's regulations established in June 2021 [3]. - For the first half of 2025, the company executed 2,381 buy transactions totaling €2,121,620.77 for 324,721 shares, while sell transactions totaled €2,170,808.76 for 330,062 shares [5][11]. Future Developments - Construction of the world's first industrial biorecycling plant is expected to restart in the second half of 2025, contingent on securing additional funding [4]. - The biorecycling demonstration plant has been operational since 2021, showcasing CARBIOS's commitment to advancing its technologies [4].

MILWAUKEE, July 8, 2025 /PRNewswire/ -- The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable contingent va ...

Core Insights - Shares of Cogent Biosciences (COGT) increased by 23.4% following the positive results from a late-stage study of bezuclastinib for treating non-advanced systemic mastocytosis (SM) patients [1][7]. Study Results - The phase III SUMMIT study met all primary and key secondary endpoints, showing significant improvements in the treatment of SM patients with bezuclastinib compared to placebo [2][9]. - Bezuclastinib treatment resulted in a mean total symptom score (TSS) reduction of 24.3 points at 24 weeks, compared to a 15.4-point reduction in the placebo group, leading to a placebo-adjusted improvement of 8.91 points [8]. - 87.4% of patients treated with bezuclastinib experienced a ≥50% reduction in serum tryptase levels, a key biomarker, while no patients in the placebo group achieved this [9]. Safety and Tolerability - Bezuclastinib was reported to be well-tolerated with a favorable safety profile, indicating its potential for chronic use in this patient population [10]. Future Plans - Cogent Biosciences plans to submit a new drug application to the FDA for bezuclastinib by the end of 2025, aiming to establish it as a new standard of care for non-advanced SM [11]. - The company is also evaluating bezuclastinib for advanced SM and gastrointestinal stromal tumors in separate pivotal studies, with top-line data expected in the second half of 2025 [12]. Market Performance - Year-to-date, Cogent Biosciences shares have increased by 19.9%, outperforming the industry, which saw a decline of 1.9% [4].

Core Insights - Bayer's subsidiary, BlueRock Therapeutics, has initiated the first patient treatment in the phase I/IIa CLARICO study with OpCT-001, an investigational iPSC-derived cell therapy for primary photoreceptor diseases [1][9] - OpCT-001 is the first iPSC-derived cell therapy tested in humans for inherited eye diseases, including retinitis pigmentosa and cone-rod dystrophy, which can cause vision loss [2][9] - The CLARICO study aims to evaluate the safety, tolerability, and clinical outcomes of OpCT-001, with a focus on safety in the phase I portion and additional safety and visual function data in the phase II part [4][9] Bayer's Stock Performance - Year-to-date, Bayer's shares have increased by 56.6%, contrasting with a 0.7% decline in the industry [7] Pipeline Developments - Bayer has expanded its pipeline to include cell therapy through the acquisition of BlueRock and gene therapy through AskBio, targeting various diseases including retinal disorders and Parkinson's disease [10] - The FDA has granted Fast Track designation to OpCT-001 for treating primary photoreceptor diseases, indicating potential for significant therapeutic advancements [11] Other Developments - Bayer is also developing bemdaneprocel (BRT-DA01) in a phase III study for Parkinson's disease, which has received Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA [12]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YOR ...